Louis Lazo Radulovic, Ph.D., M.P.H., Study Director and PK analyst is responsible for evaluation of pharmacokinetics of drugs. Dr. Radulovic has 25 years of drug development experience having worked at Warner-Lambert/Parke-Davis, Pfizer Global Research and Development, and Fulcrum Pharma Developments, Inc, prior to forming DDPS, LLC. He has worked with small molecules and biologics in several therapeutic areas, including anti-infectives, anti-virals, cancer, cardiovascular, CNS, dermatologics, diabetes, inflammation, and osteoporosis. Dr. Radulovic has served on several in-licensing due diligence teams for Warner-Lambert/Parke-Davis and Pfizer

While at Fulcrum Pharma Developments, Inc. (2007 – 2011), Dr. Radulovic designed and implemented ADME and toxicology IND-enabling programs, prepared 4 pre-IND briefing documents, 4 successful INDs, Items 2.4 and 2.6 of an eNDA for a drug/device combination, and 1 successful NDA. Dr. Radulovic reviewed and summarized clinical pharmacokinetic reports in preparation for an End-of-Phase 2 meeting. While at Warner-Lambert/Parke-Davis and Pfizer (1987 – 2007), Dr. Radulovic served on several discovery and development project teams as the pharmacokinetics/drug metabolism or toxicology representative and on numerous interdepartmental initiatives. He spent 15 years in Department of Pharmacokinetics, Dynamics & Metabolism (PDM) in positions of increasing responsibility, most notably, Therapeutic Area Head for CNS (twice) and Cardiovascular/Metabolic Disorders, and Head of the Information/Data Management and the Regulatory Submissions Groups.

In 2002, Dr. Radulovic transferred to Drug Safety Evaluation where he held positions of increasing responsibility including Nonclinical Safety Assessor, Study Director, Project Leader/Team Representative, and Development and Regulatory Strategy Site Lead within Drug Safety Research and Development (DSRD) at Pfizer Ann Arbor Laboratories. He contributed to the development of the nonclinical safety testing paradigm for dermatologics, a new therapeutic area for Pfizer. Dr. Radulovic gained extensive regulatory experience (13 INDs, 5 NDAs, 2 MAAs, and 1 JNDA), participated in teleconferences with the FDA, and presented at a FDA pre-IND meeting. He served as chair of the Pfizer

DSRD Nanotechnology Intravenous Subteam to evaluate novel excipients for delivery of anti-infectives and the Pfizer Vehicle Safety Database Subteam. Dr. Radulovic has authored over 70 publications and over 250 Parke-Davis/Pfizer internal documents.